A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
Hu ZY, Lu J, Zhao Y.
Br J Pharmacol · research-article; journal article · DOI 10.1111/bph.12609 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för alvespimycin. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
11 träffarDiscovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti-Parkinson agents.
Gao L, Zhao G, Fang JS, Yuan TY, Liu AL, Du GH.
FEBS J · research support, non-u.s. gov't; journal article · DOI 10.1111/febs.12672The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B, Yang J, Wang L.
Tumour Biol · journal article · DOI 10.1007/s13277-013-1422-7Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells.
Sun X, Bristol JA, Iwahori S, Hagemeier SR, Meng Q, Barlow EA, Fingeroth JD, Tarakanova VL, Kalejta RF, Kenney SC.
J Virol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/jvi.01671-13Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway.
Qu Z, Dong H, Xu X, Feng W, Yi X.
Diagn Pathol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1746-1596-8-70The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y.
Cell Biol Int · research support, non-u.s. gov't; journal article · DOI 10.1042/cbi20110473HSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis.
Madrigal-Matute J, Fernandez-Garcia CE, Gomez-Guerrero C, Lopez-Franco O, Muñoz-Garcia B, Egido J, Blanco-Colio LM, Martin-Ventura JL.
Cardiovasc Res · research support, non-u.s. gov't; journal article · DOI 10.1093/cvr/cvs158One-electron reduction of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: a pulse radiolysis study.
Goldstein S.
J Phys Chem A · research support, non-u.s. gov't; journal article · DOI 10.1021/jp205161vGeldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation.
Fukumoto R, Kiang JG.
Radiat Res · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1667/rr2534.1A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I.
Clin Cancer Res · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-10-1927Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis.
Wu YC, Yen WY, Lee TC, Yih LH.
Toxicol Appl Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.taap.2009.02.003